Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
NPJ Breast Cancer
|
February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
Nadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Breast Cancer Research : BCR
|
June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
Roberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Nature Communications
|
April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
NPJ Breast Cancer
|
February 18, 2022
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
Kirsten G M Aspros, Jodi M Carter, Tanya L Hoskin, et al.
JAMA
|
April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Roberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
NPJ Breast Cancer
|
February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
Nadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Breast Cancer Research : BCR
|
June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
Roberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Nature Communications
|
April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
NPJ Breast Cancer
|
February 18, 2022
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
Kirsten G M Aspros, Jodi M Carter, Tanya L Hoskin, et al.
JAMA
|
April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Roberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Page
of 12